Major Advances in Psychiatry Transform Treatment Landscape in 2025

The field of psychiatry experienced significant advancements in 2025, marked by multiple approvals from the US Food & Drug Administration (FDA) aimed at improving treatment options for various mental health disorders. These developments included the approval of new medications and expanded uses of existing treatments, which have collectively enhanced the tools available to clinicians for delivering personalized care.

New Treatments and Approvals

On November 13, 2025, the FDA granted approval to BrainsWay Ltd. for its Deep TMS system, specifically designed for adolescents aged 15 to 21 years suffering from major depressive disorder (MDD). This noninvasive device delivers 20-minute sessions daily over a period of 4 to 6 weeks, demonstrating significant reductions in depressive symptoms and associated anxiety. The approval is supported by extensive real-world data, which underscores its efficacy as a treatment option.

In a notable milestone, the FDA approved Johnson & Johnson’s esketamine nasal spray, branded as SPRAVATO®, on January 21, 2025. This approval marks it as the first monotherapy for adults with treatment-resistant depression. Subsequent Phase 4 trials revealed rapid and significant improvements in patients’ symptoms within four weeks, providing a crucial alternative for those who do not respond to traditional oral antidepressants.

Another major development came on February 24, 2025, when the FDA authorized the expanded use of Indivior’s SUBLOCADE, an extended-release buprenorphine injection for opioid use disorder. This expansion adds thigh, buttock, and upper arm as new injection sites, aiming to enhance patient adherence by simplifying the treatment regimen with reduced induction requirements and a one-hour observation period.

The FDA also initiated a label change for acetaminophen, acknowledging evidence linking its prenatal use to an increased risk of autism and ADHD. Additionally, it collaborated with GSK to approve leucovorin (Wellcovorin) for treating cerebral folate deficiency, reflecting a commitment to enhance safety and treatment options for neurological conditions.

Promising Clinical Trials

Research efforts yielded promising new therapies throughout 2025. Teva Pharmaceuticals submitted a New Drug Application (NDA) for TEV-749, an extended-release injection for schizophrenia. Data from the Phase 3 SOLARIS trial indicated efficacy and high satisfaction rates among patients and healthcare providers, offering a controlled-release alternative to oral medications.

Similarly, Otsuka Pharmaceuticals submitted an NDA for centanafadine, a novel treatment for ADHD, with Phase 3 trials showcasing significant improvements in symptoms. The drug demonstrated a first-in-class mechanism with favorable tolerability, marking it as a potential game-changer in ADHD management.

Another noteworthy entry is MM120 (LSD), which, in a Phase 2b trial by MindMed, showed significant anxiety reduction in adults with generalized anxiety disorder (GAD). A single 100 μg dose led to rapid improvements observable by day two, with effects sustained for up to 12 weeks.

In the realm of adult ADHD treatment, Axsome Therapeutics reported that its Phase 3 FOCUS trial confirmed the effectiveness of solriamfetol, achieving a 45% mean reduction in ADHD symptoms compared to placebo.

The interconnection between physical and mental health was highlighted by experts, such as Eva Parker, MD, who noted that patients with psoriasis are 1.5 times more likely to develop depression. This statistic underscores the necessity for routine mental health screenings among dermatology patients to improve overall health outcomes.

As the psychiatric landscape evolves, discussions surrounding ethical considerations in treatment have gained prominence. In a recent episode of Medical Ethics Unpacked, hosts discussed the complexities related to psychedelic therapies, including consent and cultural integration, emphasizing the need for careful navigation of these emerging treatment modalities.

Overall, 2025 has proven to be a transformative year in the field of psychiatry, with significant advancements in both treatment options and clinical understanding, providing hope for improved patient care and outcomes in mental health.